[1]
Maxwell PH. Hypoxia-inducible factor as a physiological regulator. Exp Physiol 2005; 90(6): 791-7.
[2]
Mole DR, Schlemminger I, McNeill LA, et al. 2-Oxoglutarate analogue inhibitors of HIF prolyl hydroxylase. Bioorg Med Chem Lett 2003; 13(16): 2677-80.
[3]
Yan L, Colandrea VJ, Hale JJ. Prolyl hydroxylase domain-containing protein inhibitors as stabilizers of hypoxia-inducible factor: small molecule-based therapeutics for anemia. Expert Opin Ther Pat 2010; 20(9): 1219-45.
[4]
Forristal CE, Winkler IG, Nowlan B, Barbier V, Walkinshaw G, Levesque JP. Pharmacologic stabilization of HIF-1alpha increases hematopoietic stem cell quiescence in vivo and accelerates blood recovery after severe irradiation. Blood 2013; 121(5): 759-69.
[5]
Maxwell PH, Eckardt KU. HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond. Nat Rev Nephrol 2016; 12(3): 157-68.
[6]
Beck H, Jeske M, Thede K, et al. Discovery of molidustat (BAY 85-3934): a small-molecule oral HIF-Prolyl Hydroxylase (HIF-PH) inhibitor for the treatment of renal anemia. ChemMedChem 2018; 13(10): 988-1003.
[7]
Bottcher M, Lentini S, Arens ER, et al. First-in-man-proof of concept study with molidustat: a novel selective oral HIF-prolyl hydroxylase inhibitor for the treatment of renal anaemia. Br J Clin Pharmacol 2018; 84(7): 1557-65.
[8]
Del Vecchio L, Locatelli F. Roxadustat in the treatment of anaemia in chronic kidney disease. Expert Opin Investig Drugs 2018; 27(1): 125-33.
[9]
Beuck S, Bornatsch W, Lagojda A, Schanzer W, Thevis M. Development of liquid chromatography-tandem mass spectrometry-based analytical assays for the determination of HIF stabilizers in preventive doping research. Drug Test Anal 2011; 3(11-12): 756-70.
[10]
Buisson C, Marchand A, Bailloux I, Lahaussois A, Martin L, Molina A. Detection by LC-MS/MS of HIF stabilizer FG-4592 used as a new doping agent: investigation on a positive case. J Pharm Biomed Anal 2016; 121: 181-7.
[11]
Cortez MA, Calin GA. MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases. Expert Opin Biol Ther 2009; 9(6): 703-11.
[12]
Nallamshetty S, Chan SY, Loscalzo J. Hypoxia: a master regulator of microRNA biogenesis and activity. Free Radic Biol Med 2013; 64: 20-30.
[13]
Loscalzo J. The cellular response to hypoxia: tuning the system with microRNAs. J Clin Invest 2010; 120(11): 3815-7.
[14]
Camps C, Harris AL, Ragoussis J. Regulation of hypoxia responses by microRNA expression. In: MicroRNAs in medicineEd Lawrie CH. John Wiley & Sons 2014; pp. 267-85.
[15]
Whitehead CL, Teh WT, Walker SP, Leung C, Larmour L, Tong S. Circulating microRNAs in maternal blood as potential biomarkers for fetal hypoxia in-utero. PLoS One 2013; 8(11): e78487.
[16]
Gupta S, Li L. Modulation of miRNAs in pulmonary hypertension. Int J Hypertens 2015; 2015: 169069.
[17]
Flamme I, Oehme F, Ellinghaus P, Jeske M, Keldenich J, Thuss U. Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (molidustat) stimulates erythropoietin production without hypertensive effects. PLoS One 2014; 9(11): e111838.
[18]
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25(4): 402-8.
[19]
Ramakrishnan S, Anand V, Roy S. Vascular endothelial growth factor signaling in hypoxia and inflammation. J Neuroimmune Pharmacol 2014; 9(2): 142-60.
[20]
Kapitsinou PP, Liu Q, Unger TL, et al. Hepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia. Blood 2010; 116(16): 3039-48.
[21]
Heinicke K, Prommer N, Cajigal J, Viola T, Behn C, Schmidt W. Long-term exposure to intermittent hypoxia results in increased hemoglobin mass, reduced plasma volume, and elevated erythropoietin plasma levels in man. Eur J Appl Physiol 2003; 88(6): 535-43.
[22]
Berglund B, Gennser M, Ornhagen H, Ostberg C, Wide L. Erythropoietin concentrations during 10 days of normobaric hypoxia under controlled environmental circumstances. Acta Physiol Scand 2002; 174(3): 225-9.
[23]
Koury MJ, Bondurant MC. The mechanism of erythropoietin action. Am J Kidney Dis 1991; 18(4)(Suppl. 1): 20-3.
[24]
Seeley TW, Sternlicht MD, Klaus SJ, Neff TB, Liu DY. Induction of erythropoiesis by hypoxia-inducible factor prolyl hydroxylase inhibitors without promotion of tumor initiation, progression, or metastasis in a VEGF-sensitive model of spontaneous breast cancer. Hypoxia 2017; 5: 1-9.
[25]
Ariazi JL, Duffy KJ, Adams DF, et al. Discovery and preclinical characterization of GSK1278863 (Daprodustat), a small molecule hypoxia inducible factor-prolyl hydroxylase inhibitor for anemia. J Pharmacol Exp Ther 2017; 363(3): 336-47.
[26]
Oltmanns KM, Gehring H, Rudolf S, et al. Acute hypoxia decreases plasma VEGF concentration in healthy humans. Am J Physiol Endocrinol Metab 2006; 290(3): E434-9.
[27]
Marabita F, de Candia P, Torri A, Tegner J, Abrignani S, Rossi RL. Normalization of circulating microRNA expression data obtained by quantitative real-time RT-PCR. Brief Bioinform 2016; 17(2): 204-12.
[28]
Peltier HJ, Latham GJ. Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues. RNA 2008; 14(5): 844-52.
[29]
Schlosser K, Taha M, Deng Y, Jiang B, Stewart DJ. Discordant regulation of microRNA between multiple experimental models and human pulmonary hypertension. Chest 2015; 148(2): 481-90.
[30]
Shah JS, Soon PS, Marsh DJ. A technical guide to identifying miRNA normalizersusing TaqMan Advanced miRNA Assays. Appl Biosys 2016; pp. 1-4.
[31]
Vandesompele J, De Preter K, Pattyn F, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes Genome Biol 2002; 3(7): RESEARCH0034.
[32]
Gee HE, Ivan C, Calin GA, Ivan M. HypoxamiRs and cancer: from biology to targeted therapy. Antioxid Redox Signal 2014; 21(8): 1220-38.
[33]
Brock M, Haider TJ, Vogel J, et al. The hypoxia-induced microRNA-130a controls pulmonary smooth muscle cell proliferation by directly targeting CDKN1A. Int J Biochem Cell Biol 2015; 61: 129-37.
[34]
Saito K, Kondo E, Matsushita M. MicroRNA 130 family regulates the hypoxia response signal through the P-body protein DDX6. Nucleic Acids Res 2011; 39(14): 6086-99.
[35]
Yan Y, Shi Y, Wang C, et al. Influence of a high-altitude hypoxic environment on human plasma microRNA profiles. Sci Rep 2015; 5: 15156.
[36]
Bertero T, Lu Y, Annis S, et al. Systems-level regulation of microRNA networks by miR-130/301 promotes pulmonary hypertension. J Clin Invest 2014; 124(8): 3514-28.
[37]
Liu Y, Nie H, Zhang K, et al. A feedback regulatory loop between HIF-1alpha and miR-21 in response to hypoxia in cardiomyocytes. FEBS Lett 2014; 588(17): 3137-46.
[38]
Mace TA, Collins AL, Wojcik SE, Croce CM, Lesinski GB, Bloomston M. Hypoxia induces the overexpression of microRNA-21 in pancreatic cancer cells. J Surg Res 2013; 184(2): 855-60.
[39]
Li Y, Yao M, Zhou Q, et al. Dynamic regulation of circulating microRNAs during acute exercise and long-term exercise training in basketball athletes. Front Physiol 2018; 9: 28.
[40]
Nielsen S, Akerstrom T, Rinnov A, et al. The miRNA plasma signature in response to acute aerobic exercise and endurance training. PLoS One 2014; 9(2): e87308.
[41]
Sheedy FJ. Turning 21: induction of miR-21 as a key switch in the inflammatory response. Front Immunol 2015; 6: 19.
[42]
Bruning U, Cerone L, Neufeld Z, et al. MicroRNA-155 promotes resolution of hypoxia-inducible factor 1alpha activity during prolonged hypoxia. Mol Cell Biol 2011; 31(19): 4087-96.
[43]
Huang X, Le QT, Giaccia AJ. MiR-210--micromanager of the hypoxia pathway. Trends Mol Med 2010; 16(5): 230-7.
[44]
Yan Y, Wang C, Zhou W, et al. Elevation of circulating miR-210-3p in high-altitude hypoxic environment. Front Physiol 2016; 7: 84.
[45]
Baggish AL, Hale A, Weiner RB, et al. Dynamic regulation of circulating microRNA during acute exhaustive exercise and sustained aerobic exercise training. J Physiol 2011; 589(Pt 16): 3983-94.
[46]
Charan J, Kantharia ND. How to calculate sample size in animal studies? J Pharmacol Pharmacother 2013; 4(4): 303-6.
66
7
1
1